Do guidelines for treating chest disease in children use Cochrane reviews effectively?

Prayle, Andrew; Cox, Tessy; Smith, Sherie J.; Rycroft-Malone, Joanne; Thomas, Kim S.; Hughes, Dyfrig; Smyth, Alan R.

Thorax

DOI: 10.1136/thoraxjnl-2016-208790

Published: 01/07/2018

Peer reviewed version

Citation for published version (APA):

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Supplementary information file 1.

Methods

Protocol
The protocol for this systematic review (including study eligibility criteria and statistical analysis plan) was produced in advance of the data collection, is available at the University of Nottingham ePrints server (http://eprints.nottingham.ac.uk/id/eprint/3031, http://eprints.nottingham.ac.uk/id/eprint/3032; and are available as supplementary files 2 and 3 to this manuscript.

Search strategy – for guidelines
We searched for clinical guidelines written in the UK for lower respiratory disease (including the lower airways and up to and including anatomical sites of the epiglottis and also including croup) for children (0-18 years old) in Embase, Pubmed and on individual websites of guideline commissioning agencies (search terms used and the list of all websites in supplementary file 2).

Search strategy – for Cochrane Reviews
We searched the Cochrane library for Cochrane Reviews of treatments for lower respiratory tract disease in children. The searches (for both guidelines and Cochrane Reviews) were conducted between September and December 2012.

Inclusion / exclusion – for Guidelines
We included guideline recommendations for clinical practice which were of an intervention for diseases of the lower respiratory tract in children. We excluded recommendations which did not concern interventions (e.g. diagnostic tests), and recommendations about cancer, smoking cessation, pregnancy, expert opinions and recommendations for specialists not directly affecting patients, e.g. hand washing protocols.

Inclusion / exclusion - for Cochrane reviews
For each guideline recommendation, we identified whether there was a relevant Cochrane Review in the Cochrane library. We defined a relevant Cochrane Review as one which was (i) cited by the guideline or (ii) was not cited but reviewed an intervention which was applied to the same target group and could support or contradict the guideline recommendation(s). We excluded Cochrane Reviews where they had not been published at least one year prior to the publication of the guideline, or prior to the date of the literature search undertaken for the guideline, where this date was published within the guideline. After matching the Cochrane Review to the guideline recommendation, if the guideline cited the relevant Cochrane Review anywhere within the guideline, we assumed that the authors of the guideline were aware of the Cochrane Review, and had used it in writing the guideline recommendation in question.
Cochrane review updates
Cochrane reviews are continuously updated documents. However, previous versions of Cochrane Reviews remain available for download from the Cochrane library. Therefore, for each guideline recommendation, we matched with the most recent version of the Cochrane review (published at least one year prior to the guideline). For this reason within our dataset there may be multiple versions of the same Cochrane review, each one linked to guidelines with differing publication dates.

Data extraction
We extracted from the guidelines the topic, publication year, recommendations about interventions and recommendations based on Cochrane Reviews. We also extracted data regarding the commissioning agency, the use of other high quality evidence (such as a meta-analysis, randomised controlled trial or systematic review). Where more than one commissioning agency was involved in the production of a guideline (e.g. the Scottish Intercollegiate Guidelines Network (SIGN) and the British Thoracic Society (BTS) co-produced an asthma guideline) we considered the collaboration as a new entity (i.e. a SIGN-BTS agency). The individual data items for which data were collected are listed in the study protocol.

Analysis
The agreement between the guideline and the Cochrane Review was assigned to one of four categories, (totally in agreement, partially, not in agreement, or a strong guideline but no conclusion in the Cochrane review; definitions shown in table S1). Two investigators (TC and APP) independently assessed Cochrane Reviews for relevance and agreement. Examples of categorizations are shown in table S2. Disagreements were resolved after discussion with a third party (ARS).

Sensitivity Analysis
The classification of different categorizations of agreement and disagreement requires an element of judgement. We therefore undertook a sensitivity analysis in which we examined the impact of differing categorizations of agreement upon our results. We took all the all the pairs which were “partially in agreement”, and categorized them as either “not in agreement”, or as “totally in agreement”. This allowed us to evaluate the effect of having a “partially in agreement” category upon our results.
Alternate sources of high quality evidence
As guidelines may use alternate sources of high quality evidence, we sought to establish if other
evidence had been used for each guideline recommendation. We defined alternate high quality
evidence broadly as (non-Cochrane) meta-analyses, systematic reviews or randomised controlled
trials. We categorized a guideline recommendation as using alternate high quality evidence if the
recommendation referenced sources of alternate high quality evidence. The alternate evidence did
not need to be specifically referenced in-line within the recommendation, but could be referenced
anywhere within the guideline document (we assumed that the authors of that specific
recommendation had used all of the references within the guideline).

Statistical analysis
Our primary unit of analysis (i.e. the denominator) was the individual guideline recommendations.
We calculated the proportion of guidelines (with 95% confidence intervals) which identified all,
some, or none of the relevant Cochrane Reviews. In a series of analyses using logistic regression, we
tested whether the commissioning agency, publication year (as a continuous variable) of the
guideline, topic of the guideline and the use of other high quality evidence, were associated with of
the use of Cochrane Reviews. We used a series of mixed effects models, in which the predictor
variable (e.g. commissioning agency) was modelled as a fixed effects term, with a random intercept
and slope for each guideline. We then compared the model with and without the fixed effects term
using anova, and report the resultant p value for a summary of the overall effect of the predictor
variable. We used the R packaged lme4 for the mixed effects model, using the model specification
in R formula syntax as $Y \sim X + (1 + X \mid \text{Guideline})$, where $X$ is the predictor variable (e.g.
commissioning agency), and $Y$ is a binary response of whether or not the guideline cited all the
available Cochrane evidence for that recommendation.

As each guideline recommendation could potentially be linked to multiple Cochrane Reviews, we
calculated the proportion of these links in which the Cochrane Review and guideline were in
agreement. Analyses were undertaken with R (version 3.2.0). An interactive plot showing the links
between Cochrane Reviews and guideline recommendations was designed and implemented for
modern web browsers in javascript using the programming library D3. js (http://d3js.org/). The
data generated by this study are to download along with the source code at
https://github.com/andrewprayle/Do-guidelines-for-treating-chest-disease-in-children-use-
Cochrane-reviews-effectively .
The original protocol used ordinary logistic regression to examine the association between commissioning agency, publication year, topic and alternate high quality evidence upon the likelihood of citing a Cochrane Review. However, at the request of the statistical reviewer, we changed our analysis to a mixed effects logistic regression approach, to better account for the effect of clustering between guideline recommendations within guidelines.

We performed a series of mixed effects logistic regression models to study the association between of commissioning agency, publication year, topic and alternate high quality evidence upon the likelihood of citing a Cochrane Review. Due to the sparsity of data, and that several guidelines only contributed one recommendation to the dataset, we found that several of these models failed to converge using the `glmer` function in `lme4`. We found however that removing the 3 guidelines which contributed only one recommendation to the dataset allowed the model to converge when using the `bobyqa` optimization routine, and these results are reported below.

Supplementary results
Table S3 shows the guidelines included in the study and data collected.

Of the 96 recommendations that could use Cochrane Reviews, 29% (28/96) did not use any, and 10%, (10/96) did not use all the available Cochrane Reviews. There were 140 instances where a Cochrane Review could be linked to at least one guideline recommendation. Of these 103/140 (74%) were in agreement, 13/140 (9%) were partially in agreement, 5/140 (3.5%) disagreed and 19 / 140 (13%) were strong recommendations but the Cochrane Review did not draw a conclusion.

Table S4 shows the results of the sensitivity analysis. The original analysis suggests that 103/140 (74%) recommendations from respiratory guidelines in children are in line with the Cochrane Review. The figure remains the same if the ‘partly in agreement’ and ‘not in agreement’ categories are combined. However, if the ‘partly in agreement’ and ‘totally in agreement’ categories are combined, the agreement goes up to 116/140 (83%).

Association between commissioning agency, publication year, topic and alternate high quality evidence and use of Cochrane reviews

In this series of mixed effects logistic regression models, we found no evidence of an overall effect of commissioning agency (p = 0.99), publication year (p = 0.96), topic (p = 0.96) or alternate high quality evidence (p = 0.57). However, one commissioning agency (BTS / SIGN) was significantly less likely to cite Cochrane Reviews (odds ratio 0.24, 95% confidence interval 0.06 to 0.98, p=0.04). Table S5 shows the numbers of guidelines, recommendations, odds ratios and p values for these data.
In guidelines using the SIGN methodology for grading the evidence (n=7) only 53/289 (18%) of the recommendations were based on high quality evidence derived from meta-analyses, systematic reviews or randomised controlled trials with a low risk of bias. Approximately half of the guideline recommendations (133/289 or 46%) were based on case reports, case series, expert opinions or evidence extrapolated from case control or cohort studies, usually due to lack of availability of high quality evidence.

Further discussion

If a Cochrane review exists, is up to date, and is applicable to the guideline, we believe it should be cited in guideline recommendations.

Association between of topic, commissioning agency and use of Cochrane Reviews
Of the three largest groups (by number of recommendations in our study), asthma guidelines cited Cochrane Reviews the least, and respiratory infections and cystic fibrosis used the most. Part of this difference may be due to the amount of evidence available per topic. When fewer Cochrane Reviews are available, missing one will have a bigger effect on the proportion used. However, in the field of asthma there are multiple Cochrane Reviews which are relevant to asthma guidelines. The BTS / SIGN asthma guideline was significantly less likely to cite Cochrane Reviews. However, in this and other examples, any effect of the topic of the guideline could be confounded by commissioning agency and vice versa. We hypothesised that over time guidelines become more evidence based, and we examined whether publication year and use of other evidence affected Cochrane Review use. We found no evidence that the publication year or the use of other high quality was associated with Cochrane Review use.

Other work in the field
Silagy et al(1) looked at the use of Cochrane Reviews in clinical guidelines for the cessation of smoking and found four clinical practice guidelines, of which one was from the UK. In the UK guideline, Cochrane Reviews could have been used for 16/22 (73%) of the recommendations but were used for only half of these. This is in line with our finding that 60% of guideline recommendations for respiratory disease in children used all the relevant Cochrane Reviews. Brok et al(2) studied the agreement between guidelines and Cochrane Reviews for new-borns in Denmark. They found that 24% of guideline recommendations were not in agreement with the findings of a relevant Cochrane Review (of which 6% partially agreed, and 18% did not agree).
Other factors influencing strength of recommendations
Some of the discrepancy between the strength of recommendations and the strength of the evidence could be explained by other factors which should be taken into account when considering the strength of a recommendation. The current GRADE approach (3) proposes that recommendations are dichotomised into “strong” and “weak”. GRADE proposes four determinants of the strength of a recommendation: the quality of the evidence, the balance of risks and benefits, the variability in patient preference, and cost. It should be noted that not all the guidelines which we assessed used the GRADE methodology. When collecting data on alternate high quality evidence cited in guidelines, we did not assess the quality of this evidence with the GRADE approach; this is a topic for future work.

Commentary on the study methodology
Our study is comprehensive because all relevant clinical guidelines for respiratory disease written in the UK were included. We studied the Cochrane evidence base and national guidelines for the whole field of paediatric respiratory disease, at a single time-point. At the time of our search, it was surprisingly difficult to obtain all relevant guidelines, and some may have been overlooked when the main topic was not a respiratory disease or when the guideline was not indexed or tagged as a guideline or consensus document.

We strove for repeatability in our methodology by defining a priori what would constitute a relevant Cochrane Review, and defining agreement between guideline and Cochrane Review. The categorisation of agreement and linking Cochrane Reviews to guideline recommendations was done individually by two investigators, and we acknowledge the inherent subjectivity in this categorisation. Cochrane Reviews were only linked to guideline recommendations when the target group was the same, this however might under estimate the use of Cochrane Reviews in clinical guidelines. Guideline development takes time, and for this reason we pre-specified that Cochrane Reviews should be published at least one year prior to the publication of the guideline to for us to count them as “missed” if they were not cited. We found a small numbers of recommendations which were not in agreement with the conclusions of relevant Cochrane Reviews. Due to the low numbers in this group, commenting upon contributory factors would be speculative.

Explanations for non-citation of a Cochrane review
There may be legitimate reasons for not citing a Cochrane Review (such as the guideline development group not considering the intervention to be relevant or generalizable to the UK setting). Some guideline developers, such as the National Institute for Health and Care Excellence (NICE), commission their own systematic reviews to inform key recommendations and these are not published separately. The guideline group may not include a Cochrane Review if it has not been
updated at the specified interval. We excluded from our analysis Cochrane Reviews which had been withdrawn from the Cochrane Library. The Cochrane Review may cite only one relevant trial, in which case it is reasonable for the guideline to cite the trial rather than the review. However, in most guidelines, reasons for not citing Cochrane Reviews are not given and so it appears likely that high quality evidence is being overlooked.

There may be Cochrane Reviews which overlap (for example there are several Cochrane Reviews on corticosteroids in asthma). However, we believe that the guideline should consider all the available evidence, and this should be reflected in the citations within the guideline. There are no restrictions on number of citations in guidelines (as most are electronic) unlike journal articles (where the number of citations may be restricted). We would expect the experts in the field to be aware of all of the relevant Cochrane reviews, and this to be reflected in the guideline citations.

**Limitations of this study**

A key limitation of our study is that decisions on agreement of guideline recommendations with Cochrane Reviews were sometimes hard to achieve. We took a consensus approach where two investigators categorized, with independent adjudication of a third party. However, we recognise the subjectivity of this assessment. Decisions comparing ‘partially in agreement’ and ‘totally in agreement’ were particularly difficult. In the interests of transparency our raw data are available. In supplementary Table S1 we show the results of a sensitivity analysis in which we demonstrate the impact of changing our categorisations to group all the subgroups of ‘not in agreement’ into different categories. Additionally the interactive evidence network diagram allows easy visualisation and interrogation of our data.

We defined a Cochrane review as being relevant to a guideline recommendation on the basis of the same target group of patients, and that the Cochrane review could support or contradict the guideline recommendation. A limitation of this definition is that we did not consider whether the intervention was cost effective, feasible for the NHS to adopt and whether the intervention and setting was generalizable to the UK. This could lead to us overstating the number of Cochrane reviews which were potentially relevant to guideline recommendations.

Due to time and resource constraints, we had to limit our study to guideline recommendations for interventions. It is worth noting that there are large gaps in the evidence base for diagnosis and prognosis, and future studies should be directed at understanding these gaps in more detail.
It should be noted, that although Cochrane strives to update reviews, many reviews do become out of date. In a systematic analysis of the evidence base for interventions in paediatric primary care, only 44% of systematic reviews were up to date by the Cochrane collaboration’s criteria.(4)

Although we systematically studied over 40 guidelines, of which 21 could be informed by Cochrane Reviews, which contained over one thousand recommendations, we found only a handful of recommendations which were (at least partially) at odds with the conclusions of a relevant Cochrane Reviews. A larger study with a wider scope is required to study factors which make a guideline recommendation more likely to be at odds with the conclusions of what is often the best available evidence. Additional work could also focus on conflict of interest and nationality of authors, and establish which guideline methodologies are associated with most reliably citing Cochrane Reviews.
### Additional Tables and Figures

#### Table S1. Categorisation of agreement.

<table>
<thead>
<tr>
<th>Category</th>
<th>Discrepancies</th>
<th>Definition</th>
</tr>
</thead>
</table>
| 1        | Totally in agreement | • Recommendations are the same  
• There is weak evidence from a CR to support the recommendation in the guideline, and the guideline makes an appropriate recommendation  
• Two interventions are equal to each other and the guideline promotes one for other non-efficacy/safety reasons (e.g. ease of administration, cost etc). |
| 2        | Partially in agreement | • Guideline makes a somewhat different recommendation than the CR. |
| 3        | Not in agreement | • Guideline makes a recommendation which is directly contradicted by the Cochrane Review. |
| 4        | Strong* guideline recommendation while there is no conclusion in the CR | • Guideline makes a strong recommendation while the CR concludes there is not enough evidence to make a recommendation. |

A strong guideline recommendation was one in which there was a positive statement to do something or not to do something, such as to administer a drug in a certain situation. An example of this would be to give corticosteroids for asthma at a certain dosage, or to administer an immunisation.
### Table S2. Examples of categorisations.

<table>
<thead>
<tr>
<th>Categorization type:</th>
<th>Guideline recommendation</th>
<th>Cochrane conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Totally in agreement</td>
<td>In the absence of any evidence of benefit from the use of modified infant milk formulae it is not possible to recommend it as a strategy for preventing childhood asthma.</td>
<td>A large, well conducted trial of hydrolysed formula compared to cow's milk formula is required before hydrolysed formulas is offered routinely in preference to other types of formula ...</td>
</tr>
<tr>
<td>2. Partially in agreement</td>
<td>The first choice as add-on therapy to inhaled steroids in adults and children is an inhaled long-acting beta-2 agonist which should be considered before going above a dose of 400 micrograms BDP or equivalent per day and certainly before going above 800 micrograms BDP (over 12s)</td>
<td>In adult patients who remain symptomatic on low dose inhaled steroids, the addition of a long-acting β2-agonist reduces the relative risk of exacerbations requiring systemic steroids by 17% as compared to that observed with the addition of a leukotriene receptor antagonist. [...] The results may not be generalisable to children and adolescents, or patients over 65 years.</td>
</tr>
<tr>
<td>3. Not in agreement</td>
<td>If control remains inadequate on 400 micrograms daily of an inhaled steroid plus a long-acting beta-2 agonist consider increasing inhaled steroids to 800 micrograms BDP/day</td>
<td>Current asthma guidelines recommend titration of dose to individual patient response, but the published data provide little support for dose titration above 400 mcg/d in patients with mild to moderate asthma. There are insufficient data to draw any conclusions concerning dose-response in people with severe asthma.</td>
</tr>
<tr>
<td>4. Strong guideline but no conclusion in CR</td>
<td>Immunisations should be administered independent of any considerations related to asthma.</td>
<td>This review found very limited evidence to support the routine use of pneumococcal vaccine in people with asthma. A randomised trial of vaccine efficacy in children and adults with asthma is needed.</td>
</tr>
</tbody>
</table>

The first example of each class obtained in our data collection are shown here.
Table S3. Guidelines included in the study and data collected.

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Commissioner</th>
<th>Topic</th>
<th>Year</th>
<th>Total</th>
<th>Recommendations made in guideline</th>
<th>Citation of relevant Cochrane Reviews in recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 British Guideline on the management of asthma</td>
<td>BTS, SIGN</td>
<td>Asthma</td>
<td>2009</td>
<td>146</td>
<td>75 31</td>
<td>20 11 7 13</td>
</tr>
<tr>
<td>2 Asthma (in children)- corticosteroids (TA131) (Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years)</td>
<td>NICE (TA)</td>
<td>Asthma</td>
<td>2007</td>
<td>4 4 3</td>
<td>0 3 0 0</td>
<td></td>
</tr>
<tr>
<td>3 Asthma (uncontrolled)-omalizumab (TA133)</td>
<td>NICE (TA)</td>
<td>Asthma</td>
<td>2007</td>
<td>6 5 0</td>
<td>NA NA NA NA</td>
<td></td>
</tr>
<tr>
<td>4 Asthma (children under 5)-inhaler devices (TA10)</td>
<td>NICE (TA)</td>
<td>Asthma</td>
<td>2000</td>
<td>3 3 0</td>
<td>NA NA NA NA</td>
<td></td>
</tr>
<tr>
<td>5 Asthma (older children)-inhaler devices(TA38)</td>
<td>NICE (TA)</td>
<td>Asthma</td>
<td>2002</td>
<td>5 5 0</td>
<td>NA NA NA NA</td>
<td></td>
</tr>
<tr>
<td>6 Asthma (in children)-omalizumab (TA201) (Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years)</td>
<td>NICE (TA)</td>
<td>Asthma</td>
<td>2010</td>
<td>2 2 0</td>
<td>NA NA NA NA</td>
<td></td>
</tr>
<tr>
<td>7 Methicillin-resistant staphylococcus aureus (MRSA)</td>
<td>CF Trust</td>
<td>Cystic fibrosis</td>
<td>2008</td>
<td>54 35 0</td>
<td>NA NA NA NA</td>
<td></td>
</tr>
<tr>
<td>8 Standards of care and good clinical practice for the physiotherapy management of cystic fibrosis</td>
<td>CF Trust</td>
<td>Cystic fibrosis</td>
<td>2011</td>
<td>42 31 13</td>
<td>4 10 1 2</td>
<td></td>
</tr>
<tr>
<td>9 Antibiotic treatment for cystic fibrosis</td>
<td>CF Trust</td>
<td>Cystic fibrosis</td>
<td>2009</td>
<td>135 120 13</td>
<td>10 11 0 2</td>
<td></td>
</tr>
<tr>
<td>10 Nutritional management of Cystic Fibrosis</td>
<td>CF Trust</td>
<td>Cystic fibrosis</td>
<td>2002</td>
<td>47 33 1</td>
<td>0 0 0 1</td>
<td></td>
</tr>
<tr>
<td>11 Bronchiolitis in children a national clinical guideline</td>
<td>SIGN</td>
<td>Respiratory infections</td>
<td>2006</td>
<td>32 15 4</td>
<td>4 2 0 2</td>
<td></td>
</tr>
<tr>
<td>12 Tuberculosis: Clinical Diagnosis and Management of Tuberculosis and Measures for its Prevention and Control (117)</td>
<td>NICE (CG)</td>
<td>Respiratory infections</td>
<td>2011</td>
<td>153 71 1</td>
<td>1 0 0 1</td>
<td></td>
</tr>
<tr>
<td>13 Guidelines for non-CF bronchiectasis</td>
<td>BTS</td>
<td>Respiratory infections</td>
<td>2010</td>
<td>146 43 4</td>
<td>3 2 1 1</td>
<td></td>
</tr>
<tr>
<td>14 Recommendations for the assessment and management of cough in children</td>
<td>BTS</td>
<td>Respiratory infections</td>
<td>2007</td>
<td>13 13 5</td>
<td>4 3 1 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Title</td>
<td>Authority</td>
<td>Topic</td>
<td>Year</td>
<td>Page</td>
<td>Section</td>
</tr>
<tr>
<td>---</td>
<td>-----------------------------------------------------------------------</td>
<td>-----------</td>
<td>------------------------------</td>
<td>------</td>
<td>------</td>
<td>---------</td>
</tr>
<tr>
<td>15</td>
<td>Guidelines for the management of community acquired pneumonia in children</td>
<td>BTS</td>
<td>Respiratory infections</td>
<td>2011</td>
<td>33</td>
<td>16</td>
</tr>
<tr>
<td>16</td>
<td>Influenza-zanamivir, amantadine and oseltamivir (review) (TA168)</td>
<td>NICE (TA)</td>
<td>Respiratory infections</td>
<td>2009</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>17</td>
<td>Influenza (prophylaxis)-amantadine, oseltamivir and zanamivir (TA158)</td>
<td>NICE (TA)</td>
<td>Respiratory infections</td>
<td>2008</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>18</td>
<td>Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic</td>
<td>BTS, BIS, HPA, HD</td>
<td>Respiratory infections</td>
<td>2007</td>
<td>97</td>
<td>38</td>
</tr>
<tr>
<td>19</td>
<td>Respiratory tract infections (CG69)</td>
<td>NICE (CG)</td>
<td>Respiratory infections</td>
<td>2008</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>20</td>
<td>Standards for services for children with disorders of sleep physiology</td>
<td>RCPCH</td>
<td>Sleep apnoea</td>
<td>2009</td>
<td>26</td>
<td>11</td>
</tr>
<tr>
<td>21</td>
<td>A clinical guideline for the management of children presenting with acute breathing difficulty</td>
<td>RCPCH</td>
<td>Ventilation in peri-anaesthetic/critical care</td>
<td>2002</td>
<td>61</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td>1025</td>
<td>555</td>
</tr>
</tbody>
</table>
Table S4. Results of sensitivity analysis.

<table>
<thead>
<tr>
<th>Number of recommendations</th>
<th>Totally in Agreement</th>
<th>Partially in agreement</th>
<th>Not in agreement</th>
<th>Strong guideline but no conclusion in CR</th>
<th>Overall agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original analysis</td>
<td>103</td>
<td>13</td>
<td>5</td>
<td>19</td>
<td>103/140 (74%)</td>
</tr>
<tr>
<td>Case A – combine 'partially in agreement' with 'Not in agreement'</td>
<td>103</td>
<td>0</td>
<td>18</td>
<td>19</td>
<td>103/140 (74%)</td>
</tr>
<tr>
<td>Case B – combine 'Partially in agreement' with 'Totally in agreement'</td>
<td>116</td>
<td>0</td>
<td>5</td>
<td>19</td>
<td>116/140 (83%)</td>
</tr>
</tbody>
</table>
Table S5. Analysis of the influence of disease category and commissioning agency upon the likelihood of citing all relevant Cochrane Reviews.

<table>
<thead>
<tr>
<th>Guideline parameter</th>
<th>Number of guidelines</th>
<th>Number of recommendations</th>
<th>Odds ratio of citing all the available Cochrane evidence</th>
<th>95% confidence interval</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disease category</strong>¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cystic Fibrosis</td>
<td>3</td>
<td>27</td>
<td>2.53</td>
<td>0.10 to 64.71</td>
<td>0.58</td>
</tr>
<tr>
<td>Respiratory infections</td>
<td>9</td>
<td>29</td>
<td>1.08</td>
<td>0.04 to 26.24</td>
<td>0.96</td>
</tr>
<tr>
<td>Ventilation in critical care</td>
<td>1</td>
<td>5</td>
<td>2.41</td>
<td>0.05 to 106.57</td>
<td>0.65</td>
</tr>
<tr>
<td><strong>Commissioning agency</strong>²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BTS/BIS/HPA/DH</td>
<td>1</td>
<td>13</td>
<td>0.29</td>
<td>0.69 to 7.31</td>
<td>0.26</td>
</tr>
<tr>
<td>BTS/SIGN</td>
<td>1</td>
<td>31</td>
<td>0.24</td>
<td>0.06 to 0.98</td>
<td>0.04</td>
</tr>
<tr>
<td>CF Trust</td>
<td>3</td>
<td>27</td>
<td>1.86</td>
<td>0.40 to 8.61</td>
<td>0.42</td>
</tr>
<tr>
<td>NICE</td>
<td>5</td>
<td>10</td>
<td>3.55</td>
<td>0.32 to 38.78</td>
<td>0.30</td>
</tr>
<tr>
<td>RCPCH</td>
<td>2</td>
<td>6</td>
<td>1.77</td>
<td>0.14 to 21.40</td>
<td>0.65</td>
</tr>
<tr>
<td>SIGN</td>
<td>1</td>
<td>4</td>
<td>0.44</td>
<td>0.05 to 4.37</td>
<td>0.49</td>
</tr>
</tbody>
</table>

¹ – compared to baseline of asthma (which had 34 recommendations within 2 guidelines)
² – compared to baseline of BTS (which had 13 recommendations within 3 guidelines)
BTS = British Thoracic Society. SIGN = Scottish Intercollegiate Guidelines Network. BIS = British Infection Society. HPA = Health Protection Agency. NICE = National Institute for Clinical Excellence. CF Trust = Cystic Fibrosis Trust. RCPCH = Royal College of Paediatrics and Child Health. DH = Department of Health. P value calculated using the glmer function in R (using the option of setting the optimizer as the bobyqa algorithm and nAGQ [the number of points per axis for evaluating the adaptive Gauss-Hermite approximation to the log-likelihood] as 1[a Laplace optimisation]], comparing each category to the baseline.
REFERENCES


